Visiopharm Celebrates the Opening of Its New DACH Subsidiary in Germany
Danish-based leader in augmented pathology solutions Visiopharm has opened a new subsidiary in Germany to serve as the company’s headquarters in the DACH region.
The German office allows Visiopharm to meet its customers’ needs in an agile fashion and will be focused on driving business in the pharmaceutical and academic research fields, while further translating it into the healthcare and diagnostics sphere.
Initially, the subsidiary will be staffed by three very experienced Digital Pathology veterans with experiences that span both research and diagnostics markets. Further growth of the subsidiary is expected by the fall of 2019.
“The DACH region has more segregated entities due to the federal healthcare system,” said Michael Grunkin Ph.D., CEO, and co-founder of Visiopharm. “Our German office will be focused on developing our capabilities to provide an enhanced service for them in particular, as we continue to demonstrate the value of digital pathology in academic research, healthcare and pharmaceutical development.”
Kai Remmert, DACH Sales Manager, will be heading up the office and brings a wealth of Digital Pathology sales expertise.
“I am delighted to join the team and lead the business from the new German office,” he said. “With my experience in the medical imaging industry, I see it a key strategic opportunity to drive the adoption of digital pathology through the region and achieve better patient outcomes as a result.”
The German office is in addition to Visiopharm’s head office in Medicon Valley, Copenhagen, and its further branch offices in the UK and Colorado, USA.
Following a €13.3 million investment in 2018 to fuel its international growth, Visiopharm is growing rapidly in both revenue and size. With a headcount approaching 100 employees, Visiopharm is the largest quantitative digital pathology company in the world.
Do you want to know more – contact us
About Visiopharm A/S
Visiopharm® is a world leader in Augmented Pathology™ solutions. Leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, and diagnostic pathology labs all over the world use Visiopharm’s technology for tissue-based research and diagnostics.
Its solutions use the newest advancements in artificial intelligence and deep learning to make the most comprehensive, highly configurable and accurate services for tissue analysis available on the market today.
Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 900 licenses in more than 38 countries. Company headquarters are in Denmark’s Medicon Valley, with further offices in London and Broomfield, Colorado.
For Visiopharm logos and pictures: Press Photos